Malignant hyperthermia is a pharmacogenetic disorder caused by autosomal dominant mutations in the ryanodine receptor type 1 gene. Propofol has been reported as a safe anaesthetic for malignant hyperthermia susceptible patients but has not been tested on cultured cells from patients with the ryanodine receptor type 1 mutation. The aim of this study was to determine whether propofol could trigger abnormal calcium fluxes in human myotubes isolated from malignant hyperthermia susceptible patients harbouring the native ryanodine receptor type 1 mutation. Muscle specimens were obtained from the patients to diagnose malignant hyperthermia disposition and the calcium-induced calcium release test and molecular genetic analyses were performed. Using the calcium sensitive probe Fura 2, we determined the 340/380 nm wave-length ratios by measuring alterations in calcium homeostasis in isolated myotubes from cultured skeletal muscle specimens. Two patients, one with ryanodine receptor type 1 R2508C and one with the L4838V mutation had accelerated calcium-induced calcium release rates. The 340/380 nm ratios increased when the propofol concentration exceeded 100 µM. The half-maximal activation concentrations (EC 50 ) for propofol from patients 1 and 2 were 181.1 and 420.5 µM, respectively. Increases in calcium concentrations in response to propofol dosage were limited to doses at least 100-fold greater than those used in clinical settings. These observations correlate well with clinical observations that propofol does not trigger malignant hyperthermia in susceptible humans.
Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by agents such as volatile anaesthetics and depolarising muscle relaxants that induce excessive calcium release from the sarcoplasmic reticulum (SR) in skeletal muscle 1 . Central core disease (CCD) closely resembles MH, with a congenital myopathy and muscle pathology characterised by the presence of distinct cores, interstitial fibrosis and type 2 fibre deficiencies 2 . CCD and MH both have autosomal dominant inheritance and more than 100 MH-and CCDassociated mutations have been reported in the ryanodine receptor 1 (RYR1) gene of skeletal muscle 3 . MH susceptible patients (MHS) are diagnosed in North America by a caffeine-halothane contracture test and in Europe by an in vitro contracture test. In Japan, because of limitations in muscle biopsy size and examination times, MHS is diagnosed by detecting an accelerated calcium-induced calcium (CICR) rate from the sarcoplasmic reticulum (CICR rate test). The CICR test can be performed on smaller specimens up to 48 hours after biopsy, as opposed to the six hours required for caffeine contracture or halothane caffeine contracture tests used elsewhere.
Previous reports have shown that propofol is safe as a general anaesthetic for MHS patients [4] [5] [6] . In these studies propofol was examined in MHS animals or humans by measuring general anaesthesia or by examining human muscle contraction. Propofol has not been tested on cultured cells from the patients with RYR1 mutations. Our present study measured calcium regulation in propofol-treated human cells and showed that propofol is safe for MHS patients. we investigated calcium homeostasis in human myotubes formed from cells isolated from patients harbouring the native RYR1 mutation linked to MH.
MATERIALS AND METHODS

Patients
Muscle specimens were obtained from two patients referred to Hiroshima University Hospital or the National Center of Neurology and Psychiatry for the diagnosis of MH disposition. Prior to the study, written informed consent was obtained from the patients and their families.
CICR rate test and molecular genetic methods
CICR rate tests were performed at Hiroshima University according to Endo's protocol [7] [8] . In brief, chemical skinned fibres were made from biopsied muscle tissues using saponin and then treated with different calcium concentrations (0, 0.3, 1.0, 3.0 and 10 μM). The tension of each sample was measured with a force transducer and CICR rates were calculated. CICR values above 2 SD of the normal average were defined as "accelerated". The average normal values were obtained from 12 individuals with negative in vitro contracture tests and caffeine-halothane contracture tests 9 .
Molecular genetic analyses were conducted at the National Center of Neurology and Psychiatry 10 .
Cell cultures
Skeletal muscle cells isolated from the patients were maintained in Dulbecco's modified Eagle medium (DMEM; Invitrogen, U.S.A.) supplemented with 10% heat-inactivated bovine calf serum (FBS; Sigma-Aldrich, U.S.A.) containing 1% amikacin sulphate, kanamycin sulphate (Sigma) and amphotericin b (Invitrogen), in 25 cm 2 cell culture flasks (Corning, U.S.A.) in a 5% CO 2 atmosphere at 37°C. The medium was changed every three days. After two to three weeks, the cells were plated on 35 mm dishes with a 10 mm micro-well glass bottom (MatTek, U.S.A.) and grown for 10 to 14 days in DMEM with 2% FBS until the myoblasts fused to form myotubes.
Calcium imaging
Cells were washed in Hepes-buffered salt solution (HbSS) containing 130 mM NaCl, 5.4 mM KCl, 20 mM HEPES, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 and 5.5 mM glucose, with the pH adjusted to 7.4 with NaOH. The cells were loaded with 5 μM Fura-2 AM (Dojindo, Japan) in HbSS for one hour, then excited alternately at 340 nm and 380 nm, after which fluorescence emission at 510 nm was measured using a fluorescent microscope (Nikon, Japan) equipped with a cooled high-speed digital video camera (ORCA-AG; Hamamatsu, Japan). HBSS was perfused at a rate of 1.2 ml per minute. Propofol (biomedical, France) was dissolved in dimethyl sulphoxide (DMSO; Sigma) and diluted with HbSS to make the following test concentrations: 1, 3, 10, 30, 100, 300, 1000, 3000 and 5000 M. Only cells reacting to 20 mM caffeine (Wako, Japan) with an increase in intracellular calcium concentration were used for experiments. Propofol-induced changes in Fura-2 AM fluorescence were measured and the 340/380 nm ratios were calculated using a calcium imaging system (Aquacosmos 2.5; Hamamatsu, Japan). Similarly, caffeine-induced changes in Fura-2 AM fluorescence were measured at 0.25, 0.5, 1, 2.5, 5, 10 and 20 mM. The two fluorescence ratios were converted into Ca 2+ concentrations, using a calibration curve drawn with a calibration kit (Fura-2 Calcium Imaging Calibration Kit; Invitrogen).
Data analysis
To obtain dose response curves, data for propofol and caffeine were normalised to the maximum response of 20 mM and 10 mM caffeine respectively. Data analysis was performed using PRISM software (graphPad Software Inc, USA). Values are shown as mean ± SD.
An unpaired t-test was used for statistical comparisons of mean values between samples and control. Statistical significance was set at P <0.05.
RESULTS
Patients, CICR test and molecular genetic methods
Patient 1
A 13-year-old female with congenital polyarthrogryposis and scoliosis underwent surgery for scoliosis safely with propofol. Her father had an MH episode with general anaesthesia and her sister presented with congenital myopathy. The patient's serum creatine kinase (CK) was 561 U.l -1 at rest. Prior to the surgery, a muscle biopsy was performed to diagnose MH disposition. The patient had an accelerated CICR rate (Figure 1) . genetic analysis showed a point mutation in RYR1 7522 C→T, resulting in the amino acid change R2508C in exon 47. The pathological diagnosis was myopathic changes with some fibres with cores or a core-like structure, type 1 fibre predominance and type 2B fibre deficiency. The patient was diagnosed MHS with CCD.
Patient 2
A 58-year-old male consulted with us to confirm MH, because his son had experienced an MH-related incident with general anaesthesia, although he had recently received general anaesthesia with propofol safely. The serum CK of the patient was 432 U.l -1 at rest and CICR rate was accelerated (Figure 1 ). genetic analysis demonstrated a RYR1 mutation of 14642C→g, resulting in the amino acid change L4838V in exon 101.
Controls
Ten individuals who were referred to our laboratory for MH deposition and had normal CICR rates were assigned to the control group (Figure 1) .
Calcium imaging results
The average (range) for resting calcium concentrations in the myotubes of cases 1 and 2 were 107 (42-193) and 91 (56-138) nM respectively. After application of 20 mM caffeine, the average myoplasmic calcium concentrations rose to 227 and 237 nM respectively.
The 340/380 nm ratios did not increase when propofol was within 1 to 30 μM, although it rose significantly when the concentration was greater than 100 μM ( Figure 2) . A dose-response curve was obtained by normalising the increase in myoplasmic calcium concentrations for each dose to the maximum response with 20 mM caffeine ( Figure 3) . The half-maximal activation concentrations (EC 50 ) for propofol for patients 1 and 2 were 181.1 and 420.5 μM (T1) respectively. There were no changes with DMSO at the same concentrations. 
DISCUSSION
In the present study, we found that differences in effects of propofol on in vitro calcium induced calcium release for MHS patients compared with MHN patients occurred only at concentrations well above the clinical range using cultured human cells obtained from skeletal muscle specimens. This fits well with propofol's clinical record as safe for MHS patients. For the experiments, we used myotubes formed by satellite cells with a fibre-like shape and multiple nuclei. The myotubes also shared functional properties with striated skeletal muscle cells, such as calcium release via RYR1. Using this system, the total calcium regulation of the whole cell was investigated [11] [12] .
Caffeine, a ryanodine receptor agonist, has been used as a tool to investigate ryanodine receptor stimulated calcium transients [11] [12] . In the present study, reactions to caffeine and propofol were shown only at high concentrations. Therefore no increase in the 340/380 nm ratios at lower propofol dose was regarded as non-reactivity to propofol.
Propofol is used for general anaesthesia and sedation in intensive care units at clinical concentrations ranging from 2 to 6 μg/ml, which is equivalent to 11 to 34 μM. Since the serumprotein combination rate ranges from 97 to 98%, free concentrations at these doses are assumed to be approximately 1 μM. The 340/380 nm ratios did not increase when propofol ranged from 1 to 30 μM. In the two MHS patients, the half-maximal activation concentrations (EC 50 ) for propofol were 181.1 and 420.5 μM, which are much higher than clinical concentrations. Our findings showed that intracellular calcium homeostasis did not significantly increase in response to propofol, even though the concentrations tested were more than 100-fold greater than those used in clinical settings.
In an investigation of the effects of propofol on calcium regulation in swine with MHS, it was reported that concentrations ranging from 10 to 500 μM had no effect on ryanodine receptormediated Ca ++ efflux from sarcoplasmic reticulum Percentage of 20 mM caffeine response Percentage of 20 mM caffeine response vesicles. This was considered further evidence for propofol's lack of triggering of abnormal calcium fluxes in MHS ryanodine receptor channel activity, even at concentrations more than 100-fold greater than used clinically 13 . In our study using myotubes, we investigated not only the function of RYR1 but also the total calcium regulation of whole cell and showed that calcium concentrations rose at propofol levels lower than 500 μM. Accordingly, our results are consistent with the previous study 13 . we conclude that measuring calcium homeostasis with Fura 2 was useful to test the effects of propofol.
It has previously been reported that the RYR1 mutation in patient 2 (L4838V) was responsible for MH incidents, based on its expression in Chinese hamster ovary cells in functional assay 14 .
Both the L4838L and R2508C mutations are in the distribution of sequence variations of the RYR1 gene which are pathogenic for MH 10 . Using myotubes from MHS patients, especially carriers with the mutations, propofol showed no effect at clinical concentrations. These results correlate well with the observation that clinical doses of propofol do not trigger MH in MHS patients in vivo.
There was a significant difference in the EC 50 of propofol between patient 1 and controls but not between patient 2 and controls. We studied only two MHS individuals and therefore could not make general comparisons between MHS subjects and controls. Futhermore, it was unclear whether the distinctions between the two patients were caused by variations in the mutation region. Futher studies are needed to compare MHS subjects and genetic sub-types of MHS and controls.
In conclusion, we observed propofol-induced changes in myoplasmic calcium concentrations in cultured human skeletal muscle cells obtained from carriers of the RYR1 R2508C and L4838V mutations. An increase in response to propofol was demonstrated only at concentrations 100-fold greater than clinical doses. This supports clinical observations that propofol does not trigger MH in MHS individuals.
